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ABSTRACT 
Floating Type drug delivery system retains the dosage form for a long span. They provide local delivery to specific region like stomach and 
proximal small intestine and shows better bioavailability and improve therapeutic activity and substantial benefit to patients. FDDS is one of the 
novel drug delivery system to prolong gastric retention time. Various forms of gastro retentive drug delivery system, such as floating and non- 
floating. 
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INTRODUCTION 
The high level of patient compliance in taking oral dosage 
form is due to the ease of administration, patient compliance, 
flexibility in formulation and handling of this form. Although 
tremendous advances have been seen in oral controlled drug 
delivery system during last two decades .This system has 
been of limited success. This approach is bailed with several 
physiological difficulties such as inability to restrain and 
locate the controlled drug delivery system within the desired 
region of the gastrointestinal tract (GIT) due to variable 
gastric emptying and mobility. Normal gastric residence 
times usually range between 5 minutes and   2 hours 
.Migrating myoelctric complex is characterized by four 
phases: Phase1-Period of no contraction (40-60 minutes), 
phase 2-Period of intermittent contraction (20-40 minutes), 
Phase 3-period of regular contraction at the maximal 
frequency 20 minutes and phase4-Period of transition 
between phase 3 And Phase 1 (0.5minutes) 1 (figure 1)1 
Gastro retentive system can remain in the gastric region for 
several hours and hence significantly prolong the gastric 
residence time of drugs. Prolonged gastric retention 
improves bioavailability, reduces drug waste, and improves 
solubility for drugs that are less soluble in a high ph 
environment. It has applications also for local drug delivery 
to the stomach and proximal.2Slowed mobility of the 
gastrointestinal tract by concomitant administration of drugs 
or pharmaceutical excipient also increases gastric retention 
of drug. These efforts resulted in GRDSs that where designed, 
in large part, based on the following approaches. (Figure: 2)3  
Low density form of the DF that    causes buoyancy in gastric 
fluid. 
High density DF that is retained in the bottom of the 
stomach. 
Bio adhesion to the stomach mucosa. 
Expansion by swelling or unfolding to a large size which 
limits passage of dosage form through the pyloric sphincter.3  
 
Figure 1: Schematic Representation of Interdigestive 
Motility 
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Figure 2:Types of Gastro - retentive drug delivery system 
CLASSIFICATION OF FLOATING TYPE DRUG 
DELIVERY SYSTEM 
A.Single Unit Floating Dosage System 
a. Effervescent System (Gas Generating System) 
b. Non-effervescent Systems 
B.Multiple Unit Floating Dosage Systems 
a. Non- effervescent systems 
b. Effervescent System (Gas- Generating System) 
c. Hollow Microsphere 
d. Raft Forming Systems4 
A. Single Unit Dosage Form 
a. Effervescent System (Gas-Generating System) 
effervescent system are matrix type of systems this are 
prepared with the help of swell able polymers such as 
methylcellulose and chitosan and various effervescent 
components like sodium bicarbonate, citric acid and tartaric 
acid or chamber containing a liquid that gaffes at body 
temperature.(Fig:3)1 The optimal stoichiometric  ratio of 
citric acid and sodium bicarbonate for gas generation is 
reported to be 0.76:1. The common approach for preparing 
these system involves resin beads loaded with bicarbonate 
and coated with ethylcellulose.Excipient used most 
commonly in these system include HPMC, polyacrylate 
polymers, polyvinyl acetate, carbopol ,agar sodium alginate, 
calcium chloride, polyethylene oxide and  polycarbonates4 . 
 
Figure: 3 Gas-Generating System 
b. Non-effervescent System 
One or more gel forming, highly swell able, cellulosic 
hydrocolloids (e.g.  hydroxyl  ethyl  cellulose, hydroxyl propy
l cellulose and sodium carboxyl methyl 
cellulose),  polysaccharides,    or  matrix  forming  polymers(
e.g.,  polycarbophil,  polyacrylate,  and  polystyrene)  are  inc
orporated  in high level (20 75% w/w) to tablets or capsules. 
For the preparation of these types of systems, the drug and t
he gel‐forming hydrocolloid are mixed thoroughly. After oral 
administration this dosage form swells in contact with gastri
c fluids and attains  a  bulk  density  of <1.5 
B. Multiple Unit Floating Dosage Form 
a. Non-effervescent system 
 Alginate Beads 
They were made using a combination and low methoxylated 
pectin. Spherical beads of approximately 2.5 mm in diameter 
can be prepared by dropping a sodium alginate solution in to 
aqueous solutions of calcium chloride, causing precipitation 
of calcium alginate. The beads are then separated snap and 
frozen in liquid nitrogen, and freeze dried at -40° for 24 h, 
leading to the formation of porous system, which can 
maintain a floating force over 12 h. Yong-Dan Tang et. Al 
prepared alginate beads based on the above method for the 
sustained release of both hydrophobic and hydrophilic 
drugs. They added sunflower oil in the beads and found the 
beads floating for 24 hours. The hydrophobic drug ibuprofen 
was released from this system for 24 hours due to oil 
partitioning.6 
 b. Effervescent System 
 Floating pills 
These systems consist of sustained release pills as ‘seeds’ 
surrounded by double layers. The inner layer consists of 
effervescent agents like sodium carbonate while the outer 
layer is of swell able polymer like polyvinyl acetate. When 
this system is immersed in to dissolution medium at body 
temp, it sinks at once and then forms swollen pills like 
balloons which then float as they have lower density. This 
lower density is due to generation and entrapment of CO2 
within the system7 (Fig. 4)7 
 
 
                                      Figure 4: 
(A) Multiple-unit oral floating drug delivery system. 
(B) Working principle of effervescent floating drug 
delivery system. 
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c. Microballoons / Hollow microspheres 
 These are loaded with drugs in their other polymer shelf 
were prepared by simple solvent evaporation. (Figure 5)1 to 
prolong the gastric retention time (GRT) of the dosage form. . 
Polycarbonate,Eudrgit S, Cellulose acetate, calcium alginte 
agar and low methoxylted pectin re commonly used s 
polymers in preperation  of hollow microsphere. Buoyancy 
and drug release are dependent  on quantity of etc. Buoyancy 
and drug release from dosage form are dependent on 
quantity of polymers, the plasticizer polymer ratio and the 
solvent used for formulation. The micro balloons floated 
continuously over the surface of an acidic dissolution media 
containing surfactant for >12 hours.8Buoyancy and drug 
release are dependent  on quantity of polymer the 
plasticizer- polymer rtio and the solvent used.1,8 
 
Figure: 5 Micro ballons 
D. Raft Forming System 
On contact with gastrict fluid  A gel- forming solution ( 
sodium alginate solutn containing carbonate or bicarbonate) 
swells and forms a viscous cohesive gel containing 
entrapped CO2 bubbles.1 Which forms raft layer on top of 
gastric fluid  which release drugs slowly in stomach . such 
formation typically contains antacids such as aluminium 
hydroxide or calcium carbonate to reduce gastric acidity . 
They are often used for gastro esophageal reflux treatment 
as with liquid gaviscon9     ( GlasxoSmithline) (FIG.6)10 
 
Figure: 6 Barrier formed by a raft-forming system 
MECHANISM OF FDDS 
There are various attempts have been made to reatain the 
dosage form in the stomach as a way of    increaseing the 
retention time.   These attempts include introdusing  the 
floating dosage form as gas generating system and swelling  
system modified shape system . Gastric emptying delaying 
devices and co- administration of gastric-emptying delaying 
drugs. Among these, thefloating dosage form have been most 
commonly used.Floating drug delivery systems have a bulk 
density less than gastric fluid and so remain buoyant in the 
stomach without affecting the gastric emptying rate for a 
prolong period of time. While the system is floating on the 
gastric content , (fig.7a)11 the drug is released slowly at the 
desired rate from the system. This result in an increased 
GRT, better control of the fluctuation in plasma drug 
concentration .    After the Release Of Drug, The Residual 
System Is emptied from the  stomach .However ,beside  a 
minimal gastric content needed to allow the proper 
acheivement of the buoancy retention principle ,a minimal 
level of  floating force(F) is also requred to keep the dosage 
form reliably buoyant on the surface of the meal. To meaure 
the floating force kinetic, a novel apparatus fr determination 
of resultant weight has been reported in the literature. The 
apparatus operates by measuring continuosly the force 
equivalent to F is on the higher positive side (fig.7b)11 .   
apparatus help in optimizing FDDS with respect to stability 
and durability of floating forces produced in order to prevent 
the drawback of unforeseeable intragastric buoyancy 
capability variations.11 
 
a                                        b                                       c 
Figure: 7 Different mechanisms of floating systems. 
      F =F buoyancy-F gravity=(Df-Ds)gv 
      Where,F= total vertical force 
      Df=fluid density 
      Ds= Object density 
      V= volume and 
      G= acceleration due o gravity 
FACTORS AFFECTING FDDS  
Density:  Floating is a function of dosage form buoyancy that 
is dependent on the density. 
Shape of the dosage form:   ring haped and Tetrahedron  
device with flexural modules of48 and 22.5 kilo pounds per 
squares inch (KSI) are reported to have better floating, 90% 
to100% retention at 24hours  as compared with other 
shapes.12 
Concomitant drug administration: Anticholinergic like 
atropine and propantheline, prokinetic agens like 
metoclopramide and cisapride;can affect floating  time 
Fed or Unfed State:Under fasting conditions,the gi mobility 
is characterized by periods of strng motor activty or the 
migrating myoelectric complex (MMC) that occurs every 1.5 
to 2 hours. 
Nature of meal: Feeding of indigistible plymers or fatty acid 
salts can change the motolity pattern of the stomach to a fed 
state, thus decreasing the gastric emptying rate and 
prolonging drug release. 
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Caloric content and feeding frequency: Floating can be 
incresed by four to 10hours with ameal that is high in 
protein and fats. The floating can increase by over 
400minutes when successive meals are given compared with 
a singal meal dueti low frequency of MMC 
Age: Elderly people, especially those over 70, have a 
significanly longer; floting, Disease condition such as dabetes 
and crohn`s disease etc also affect drug delivery. 
Posture: Floating can vry between supine and upright 
ambulatory states of the patents.13 
ADVANTAGES OF FDDS 
Sustained drug delivery: A floating drug delivery system 
can remain in the stomach for several hours and the 
assumed prolongation in the gastric retention is postulated 
to cause sustained drug release behaviour. 
Site-specific drug delivery: Targeting of drug14 to stomach 
appears to be useful for all substances intended to produce a 
lasting local action on the gastro duodenal wall. 
Pharmacokinetic advantage: In addition, with the total 
gastrointestinal transit duration is increased, a greater 
amount of drug may be delivered and thus the relative 
bioavailability will consequently be increased. 
Reduced counter-activity of the body: Slow input of the 
drug into the body was shown to minimize the counter 
activity leading to higher drug efficiency.11 
Improves patient compliance.  
Freedom from incompatibilities between drug and excipients 
especially with buffers. 
Better therapeutic effect of short half life drugs can be 
achieved.  
Gastric retention time is increased because of buoyancy.  
Site specific drug delivery to the stomach can be 
achieved.15,16 
DISADVANTAGES OF FDDS 
These systems require a high level of fluid in the stomach for 
drug delivery to float and work efficiently-coat, water.  
The drugs that are significantly absorbed through out 
gastrointestinal tract, which undergo significant first pass 
metabolism, are only desirable candidate.  
Gastric Irritation due to the presence of some drug in the 
Floating Type Drug Delivery System. 
These systems require a high level of fluid in the stomach for 
drug delivery to float however this can be overcome by using 
low density polymers.11 
The release rate of the controlled release dosage form varies 
from a variety of factors like rate of food transit through the 
drug. 3) Potential toxicity due to loss of integrity of drugs.  
The dosage forms should be administered with more amount 
of water (200-250ml).  
These dosage forms should not be crushed or chewed.15 
PROBABLE CANDIDATES FOR FDDS 
Following are the probable candidates, but not limited to, for 
gastro retentive drug delivery system: 
Drugs required exerting local therapeutic action in the 
stomach: antacids, anti-H.pylori agents, misoprostol  
Drugs that have narrow absorption window in stomach or 
upper parts of the small intestine, e.g., furosemide, 
riboflavine-5-phosphate17  
EVALUATION PARAMETER OF FDDS 
A . In Vitro Methods 
1. Floating Lag Time And Floating Time 
It is the time taken by the tablet to emerge on to the surface 
of dissolution medium and is expressed in seconds or 
minutes.18 In (fig 8)17,18 
 
Figure 8: 
 2. Dissolution Study 
Gohel et al proposed a more relevent in vitro dissolution 
method to evaluate a floating drug   delivery systems.1The in 
vitro release study for all the formulations were carried out 
by USP Dissolution Test Apparatus Type-II. The temperature 
of the dissolution medium (0.1 M HCl, 900 ml) was 
maintained at 370C with a stirring rate of 50 rpm ,then 5ml 
of dissolution medium was taken out at intervals of 1,2,3&4 
hours. Exactly 5ml of fresh buffer was added to the 
dissolution vessel after each withdrawal, to maintain a 
constant volume. Then the withdrawal samples were 
analyzed by using a U.V 19, 20,21(fig:9)1 
 
Figure 9: In vitro dissolution method 
3. Resultant Weight Test 
An in Vitro measurng apparatus has been conceived to 
determine the real floating capabilities of buoyant dosage 
forms as a funtion of time. It operates by measuring the force 
equivalent to the force F required to keep the object totally 
submerged in the fluid.(fig:10)1 
The following equation by which weight are tested, 
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  F = F buoy – F grav 
  F = d f Gv – d s Gv = (d f – d s ) Gv 
  F = ( df – M / V ) Gv20 
 
Figure 10: Effect of various forces on floating 
B. In Vivo Method 
1. X-Ray Method 
X- Ray is a very polular evaluation parameter for floating 
dosage form now a day. It help to locate dosage form in the 
G.I.T and by which one can predict ane crrelate the gastrict 
emptying time and the passge of dosage form in the GIT.1,4,23 
2. Gastroscopy 
 It comprises of peroral endoscopy, used with a fibereoptic 
and video system. It is suggested       that gastroscopy may be 
used to inspect visually the effect of prolonged stay in 
stomach milieu ion the FDDS.1,23 
 3. Utrasonography 
Ultrasonic waves reflected substantially different acoustic 
impedances across interface enables the imaging of some 
abdominal organs. Most DFs not have sharp acoustic   
mismatches  result across their interface with the 
physiological milieu. Therefore, This  is not routingly used 
for the evaluation of Floating Type Drug Delivery System.1,23 
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